• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤促凝剂诱导的纤维蛋白形成增强了乳腺癌细胞产生的尿激酶活性。

Fibrin formation induced by tumor procoagulants enhances urokinase activity produced by mammary carcinoma cells.

作者信息

Alonso D F, De Lorenzo M S, Tejera A M, Gomez D E

机构信息

Department of Science and Technology, Quilmes National University, Buenos Aires, 1876, Argentina.

出版信息

Oncol Rep. 1998 Jan-Feb;5(1):209-12.

PMID:9458324
Abstract

We have examined the relationship between the procoagulant activity of F3II mouse mammary carcinoma cells and the production of urokinase, a profibrinolytic serine protease involved in tumor invasion and hematogenous metastasis. F3II cells were capable of inducing the conversion of purified fibrinogen to fibrin in the presence of calcium and plasma traces. Immunocytochemical examination of semi-confluent monolayers demonstrated that F3II cells also synthesized high levels of urokinase. Although fibrinogen did not modify profibrinolytic activity produced by F3II monolayers, fibrin formation increased tumor-derived urokinase activity by two-fold. The present data provide new insights into the cooperative role of coagulation and fibrinolysis facilitating and perpetuating tumor invasion.

摘要

我们研究了F3II小鼠乳腺癌细胞的促凝血活性与尿激酶产生之间的关系,尿激酶是一种参与肿瘤侵袭和血行转移的纤维蛋白溶解丝氨酸蛋白酶。F3II细胞在存在钙和微量血浆的情况下能够诱导纯化的纤维蛋白原转化为纤维蛋白。对半汇合单层细胞的免疫细胞化学检查表明,F3II细胞也合成高水平的尿激酶。尽管纤维蛋白原不会改变F3II单层细胞产生的纤维蛋白溶解活性,但纤维蛋白的形成使肿瘤来源的尿激酶活性增加了两倍。目前的数据为凝血和纤维蛋白溶解在促进和维持肿瘤侵袭中的协同作用提供了新的见解。

相似文献

1
Fibrin formation induced by tumor procoagulants enhances urokinase activity produced by mammary carcinoma cells.肿瘤促凝剂诱导的纤维蛋白形成增强了乳腺癌细胞产生的尿激酶活性。
Oncol Rep. 1998 Jan-Feb;5(1):209-12.
2
Inhibition of mammary tumor cell adhesion, migration, and invasion by the selective synthetic urokinase inhibitor B428.选择性合成尿激酶抑制剂B428对乳腺肿瘤细胞黏附、迁移和侵袭的抑制作用
Anticancer Res. 1998 Nov-Dec;18(6A):4499-504.
3
Characterization of F3II, a sarcomatoid mammary carcinoma cell line originated from a clonal subpopulation of a mouse adenocarcinoma.F3II的特征描述,F3II是一种源自小鼠腺癌克隆亚群的肉瘤样乳腺癌细胞系。
J Surg Oncol. 1996 Aug;62(4):288-97. doi: 10.1002/(SICI)1096-9098(199608)62:4<288::AID-JSO14>3.0.CO;2-1.
4
Combined treatment with verapamil, a calcium channel blocker, and B428, a synthetic uPA inhibitor, impairs the metastatic ability of a murine mammary carcinoma.钙通道阻滞剂维拉帕米与合成的尿激酶型纤溶酶原激活剂抑制剂B428联合治疗会损害小鼠乳腺癌的转移能力。
Oncol Rep. 2003 May-Jun;10(3):725-32.
5
Regulation of urokinase plasminogen activator (uPA) activity by E-cadherin and hormones in mammary epithelial cells.E-钙黏蛋白和激素对乳腺上皮细胞中尿激酶型纤溶酶原激活剂(uPA)活性的调节
J Cell Physiol. 1999 Oct;181(1):1-13. doi: 10.1002/(SICI)1097-4652(199910)181:1<1::AID-JCP1>3.0.CO;2-B.
6
Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).可溶性尿激酶型纤溶酶原激活物受体(CD87)过表达可减少乳腺癌肿瘤生长及肺转移。
Cancer Gene Ther. 2000 Feb;7(2):292-9. doi: 10.1038/sj.cgt.7700144.
7
Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model.使用uPA基因敲除和免疫缺陷异种移植联合模型,获得关于基质尿激酶型纤溶酶原激活剂(uPA)在实验性人类乳腺癌生长中重要性的直接证据。
Cancer Res. 2001 Jan 15;61(2):532-7.
8
Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.同基因乳腺癌模型中尿激酶的蛋白酶活性与肿瘤进展
J Natl Cancer Inst. 2006 Jun 7;98(11):756-64. doi: 10.1093/jnci/djj208.
9
Soluble urokinase receptor released from human carcinoma cells: a plasma parameter for xenograft tumour studies.从人癌细胞释放的可溶性尿激酶受体:异种移植肿瘤研究的血浆参数
Br J Cancer. 1999 Sep;81(2):203-11. doi: 10.1038/sj.bjc.6690678.
10
Retinoic acid modulates extracellular urokinase-type plasminogen activator activity in DU-145 human prostatic carcinoma cells.视黄酸调节DU-145人前列腺癌细胞中细胞外尿激酶型纤溶酶原激活剂的活性。
Clin Cancer Res. 1995 Jul;1(7):747-53.